The FDA has proposed ending the use of a common ingredient found in many cold and allergy medicines — and some pharmacies ...

The FDA designated 166 products under its breakthrough devices program in its most recent financial year, reversing the ...

Belski is especially bullish on small- and mid-cap equities, calling them “the golden child of the next decade. I think that ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on November 11. Uy Ear’s rating ...

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals' liver disease drug, ...

Donald Trump returning to the White House triggered new index records in the US, and major UK companies are likely to feel ...

Harvey Jones thought he was getting a bargain when he snapped up these too much-loved FTSE 100 dividend growth stocks. Now they're getting on his nerves. The post These 2 former stock market darlings ...

The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

While the numbers slumped in Q3 2024, this was expected, especially as reported earnings absorbed Zantac related payouts. They are unlikely to impact full year figures, however. In the meantime ...

Having removed uncertainty by resolving the vast majority of Zantac litigation cases in the ... The Warwickshire-based firm last month scaled back estimates for 2024 due to supply chain disruption ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...